老年骨质疏松症临床诊断及治疗药物研究进展

Abstract
Figure/Table
References (48)
Related Citation (15)

Download: PDF (702 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Osteoporosis is currently the most common chronic metabolic bone disease in clinical practice,with a particularly high incidence in the elderly.The trigger for osteoporosis is an imbalance between bone resorption and bone formation in the patient's body.Aging,end of menstruation,nutritional disorders,and medication use can all trigger osteoporosis.Osteoporosis patients often have a series of symptoms such as fractures,systemic pain,impaired mobility,functional impairment,and susceptibility to infection.Because of its high incidence rate and high mortality rate,osteoporosis has become a very serious health problem in China and even the world.There is still some controversy regarding the clinical diagnostic criteria for elderly patients with osteoporosis.New diagnostic technologies,including X-ray computed tomography,high-resolution peripheral quantitative X-ray computed tomography,and quantitative ultrasound,have gradually been applied in clinical practice.At present,the main clinical drug choices for osteoporosis are anti resorption and anabolic drugs.In addition,combination therapy and new drugs are also steadily advancing.There are a wide variety of drugs for this disease,with new and old ones varying,and the advantages and disadvantages coexist,making it very difficult to identify patients.This article is based on the latest progress in research on elderly osteoporosis,focusing on its clinical diagnosis and drug treatment.

Key words： Osteoporosis Conventional drugs New forms of treatment Combination therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I13/170

[1]	Compston JE，Mcclung MR，Leslie WD.Osteoporosis[J].Lancet，2019，393（10169）：364-376.
[2]	Cotts KG，Cifu AS.Treatment of Osteoporosis[J].JAMA，2018，319（10）：1040-1041.
[3]	Wang Y，Tao Y，Hyman ME，et al.Osteoporosis in china[J].Osteoporos Int，2009，20（10）：1651-1662.
[4]	Crandall CJ，Ensrud KE.Osteoporosis Screening in Younger Postmenopausal Women[J].JAMA，2020，323（4）：367-368.
[5]	Genant HK，Cooper C，Pprp G，et al.Interim report and recommendations of the World Health Organization task-force for osteoporosis[J].Osteoporos Int，1999，10：259-264.
[6]	Todd J，Robinson R.Osteoporosis and exercise [J].Postgrad Med.J，2003，79：320-323.
[7]	Sozen T，Ozisik L，Basaran NC.An overview and management of osteoporosis[J].Eur J Rheumatol，2017，4：46-56.
[8]	Group WS.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.Report of a WHO Study Group[J].World Health Organ Tech Rep Ser，1994，843：1-129.
[9]	Schuit S，Van Der Klift M，Weel A，et al.Fracture incidence and association with bone mineral density in elderly men and women：The Rotterdam Study[J].Bone，2004，34：195-202.
[10]	Brown JP.Long-Term Treatment of Postmenopausal Osteoporosis[J].Endocrinol Metab（Seoul），2021，36（3）：544-552.
[11]	ACOG Committee on Clinical Practice Guidelines-Gynecology.Management of Postmenopausal Osteoporosis[J].Obstet Gynecol，2022，139（4）：698-717.
[12]	Shang J，Zhou C，Jiang C，et al.Recent developments in nanomaterials for upgrading treatment of orthopedics diseases[J].Front Bioeng Biotechnol，2023，11：1221365.
[13]	Chen JL，Liu Y，Bi YF，et al.Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis[J].World J Gastroenterol，2023，29（29）：4580-4592.
[14]	Sturznickel J，Butscheidt S，Amling M，et al.Dynamics of Skeletal Status under Optimized Management during Subsequent Pregnancy in Three Women with a History of Pregnancy-and Lactation-Associated Osteoporosis Carrying pathogenic Variants in WNT1 and LRP5 [J].JBMR Plus，2023，7（8）：e10779.
[15]	Liu D，Hu Z，Tang GZ，et al.Identification of biomarkers associated with oxidative stress-related genes in postmenopausal osteoporosis[J].Cell Mol Biol（Noisy-le-grand），2023，69（6）：186-192.
[16]	Meng F，Yu Y，Tian Y，et al.A potential therapeutic drug for osteoporosis：prospect for osteogenic LncRNAs[J].Front Endocrinol（Lausanne），2023，14：1219433.
[17]	Wong SK，Mohamad NV，Jayusman PA，et al.A Review on the Crosstalk between Insulin and Wnt/β-Catenin Signalling for Bone Health[J].Int J Mol Sci，2023，24（15）：12441.
[18]	Huang W，Gong GY，Yan L.ER Stress，the Unfolded Protein Response and Osteoclastogenesis：A Review[J].Biomolecules，2023，13（7）：1050.
[19]	Han BK，Yoon H，Kim KH，et al.Inhibitory Effects of Wheat Sprouts Extract on RANKL-Induced Osteoclast Differentiation via Suppressing MAPK and NFATc1 Signaling Pathways[J].J Med Food，2023，26（7）：480-488.
[20]	Dilworth L，Stennett D，Omoruyi F.Cellular and Molecular Activities of IP6 in Disease Prevention and Therapy [J].Biomolecules，2023，13（6）：972.
[21]	Rothzerg E，Erber WN，Gibbons CLMH，et al.Osteohematology：To be or Notch to be[J].J Cell Physiol，2023，238（7）：1478-1491.
[22]	Gan J，Deng X，Le Y，et al.The Development of Naringin for Use against Bone and Cartilage Disorders[J].Molecules，2023，28（9）：3716.
[23]	Russell RGG.Bisphosphonates：The first 40 years[J].Bone，2011，49：2-19.
[24]	Xie L，Fang GB，Zhang GC.The role of ferroptosis in metabolic diseases[J].Biochim Biophys Acta Mol Cell Res，2023，1870（6）：119480.
[25]	Zhou J，Ma X，Wang T，et al.Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis：A systematic review with network meta-analyses[J].Osteoporos Int，2016，27：3289-3300.
[26]	Zhou J，Wang T，Zhap X，et al.Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis：A systematic review with network meta-analyses[J].Rheumatol Ther，2016，3：117-128.
[27]	Wei H，Zhao Y，Xiang L.Bone health in inflammatory bowel disease[J].Expert Rev Gastroenterol Hepatol，2023，20：1-15.
[28]	Wang B，Vashishth D.Advanced glycation and glycoxidation end products in bone[J].Bone，2023，12，176：116880.
[29]	Anastasilakis AD，Toulis KA，Polyzos SA，et al.Long-term treatment of osteoporosis：Safety and efficacy appraisal of denosumab.Clin[J].Risk Manag，2012，8：295-306.
[30]	Ma C，Yu R，Li J，et al.Targeting proteostasis network in osteoporosis：Pathological mechanisms and therapeutic implications[J].Ageing Res Rev，2023，90：102024.
[31]	Vorrius B，Qiao Z，Ge J，et al.Smart Strategies to Overcome Drug Delivery Challenges in the Musculoskeletal System[J].Pharmaceuticals（Basel），2023，16（7）：967.
[32]	Ballesteros J，Rivas D，Duque G.The Role of the Kynurenine Pathway in the Pathophysiology of Frailty，Sarcopenia，and Osteoporosis[J].Nutrients，2023，15（14）：3132.
[33]	Hart DA.Regulation of Bone by Mechanical Loading，Sex Hormones，and Nerves：Integration of Such Regulatory Complexity and Implications for Bone Loss during Space Flight and Post-Menopausal Osteoporosis[J].Biomolecules，2023，13（7）：1136.
[34]	Dvan I，Fakurazi S，Alias E，et al.Astaxanthin as a Potent Antioxidant for Promoting Bone Health：An Up-to-Date Review[J].Antioxidants（Basel），2023，12（7）：1480.
[35]	Cummings SR，Ensrud K，Delmas PD，et al.Lasofoxifene in postmenopausal women with osteoporosis[J].N Eng J Med，2010，362：686-696.
[36]	Bolt J，Sandhu S，Mohammadi A.Effect of Coenzyme Q10 Supplementation on Sarcopenia，Frailty，and Falls：A Scoping Review[J].J Nutr Health Aging，2023，27（7）：586-592.
[37]	Hattersley G，Dean T，Corbin BA，et al.Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling[J].Endocrinology，2016，157：141-149.
[38]	Miller SA，ST Onge EL，Whalen KL.Romosozumab：A Novel Agent in the Treatment for Postmenopausal Osteoporosis[J].J Pharm Technol，2021，37（1）：45-52.
[39]	Cosman F，Crittenden DB，Adachi JD，et al.Romosozumab treatment in postmenopausal women with osteoporosis[J].N Eng J Med，2016，375：1532-1543.
[40]	Chuang TL，Lin CH，Wang YF.Effects of vegetarian diet on bone mineral density[J].Tzu Chi Med J，2020，33（2）：128-134.
[41]	Yang Y，Tseng WJ，Wang B.Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1，25-Dihydroxyvitamin D/osteocalcin Signaling Pathway[J].Endocrinology，2023，164（9）：bqad117.
[42]	Kuhad A.The Role of Vitamin D Levels in Early Dental Implant Failure[J].J Long Term Eff Med Implants，2023，33（4）：1-8.
[43]	O'Donnell S，Mpher D，THOMAS K，et al.Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls[J].J Bone Min Res，2008，26：531-542.
[44]	Papadimitropoulos E，Wells G，SHEA B，et al.Meta-analyses of therapies for postmenopausal osteoporosis.Ⅷ ：Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women[J].Endocr Rev，2002，23：560-569.
[45]	Lou S，Lv H，Yin P，et al.Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis：A systematic review and meta-analysis of randomized controlled trials[J].Osteoporos Int，2019，30：59-70.
[46]	Nagaoka M，Maeda T，Moriwaki S，et al.Petunidin，a b-ring 5'-O-methylated derivative of delphinidin，stimulates osteoblastogenesis and reduces srankl-induced bone loss[J].Int J Mol Sci，2019，20：2795.
[47]	Park E，Kim J，Kim MC，et al.Anti-osteoporotic effects of kukoamine b isolated from lycii radicis cortex extract on osteoblast and osteoclast cells and ovariectomized osteoporosis model mice[J].Int J Mol Sci，2019，20：2784.
[48]	Capdevilla-Reniu A，Navarro-Lopez M，Lopez-Soto A.Osteoporotic vertebral fractures：A diagnostic challenge in the 21st century[J].Rev Clin Esp（Barc），2021，221（2）：118-124.